Lindong Li

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology · 2021 · 1.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2021 · 319 citations

Medicine, Oncology, Pharmacology +10

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Shukui Qin, Zhenggang Ren, Yin‐Hsun Feng et al. · Liver Cancer · 2021 · 129 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +12

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

Renchi Yang, Shujie Wang, Xuefeng Wang et al. · Research and Practice in Thrombosis and Haemostasis · 2022 · 71 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +10

Small public space vitality analysis and evaluation based on human trajectory modeling using video data

Tong Niu, Linbo Qing, Longmei Han et al. · Building and Environment · 2022 · 71 citations

Social Sciences, Urban Studies, Built Environment +11